

### Nanomi, Pushing the boundaries

Chiel Welink Analytical Chemist

Thijs DuursmaProcess Development Engineer



May 28th 2025

# My background in a nutshell

#### **Chiel Welink**

Analytical chemist

<u> 2015 – 2019</u>	BSc in Chemistry, at Saxion Enschede
2020 – now	Analytical Chemist , Nanomi

Nanomi, Pushing the boundaries





# My background in a nutshell

#### Thijs Duursma

Process Development Engineer

<u>2015 – 2019 </u>	Bachelor Chemistry, Saxion Enschede
2019 – 2020	Jr. Process Development Engineer, Nanomi
<u> 2020 – 2022</u>	Master Applied Nanotechnology, Saxion Enschede
2023 – now	Process Development Engineer, Nanomi

Nanomi, Pushing the boundaries





### Nanomi – The Netherlands



Located in the green surroundings of Oldenzaal, Twente!



### Nanomi – The Netherlands

Nanomi is a leader in the field of microsphere and nanoparticle development of long-acting release injectables, and a subsidiary of Lupin Ltd. India.

Founded in 2004 as spin-off of the University of Twente. Acquired by Lupin in 2014.

Lupin's **R&D Center** of Excellence for **complex long-acting injectables**.

Therapeutic Areas:

Generics & value-added drugs.

- Our lead program is a Generic in antipsychotics; a long-acting injectable, predominantly for the US market. Goal date for commercial launch July 2025.
- New 505(b)2/value-added drugs. Portfolio is being established with potential hits in neuro-psy, respiratory, diabetes and obesity. Also predominantly for the US market.
- CDMO business building strategic partnerships for therapeutic areas and geographies outside Lupin's strategic focus.

Market Approach: Sales through Lupin Inc US, and possibly other Lupin entities / strategic partners.





### The team

- We have an **enthusiastic team** with ambitious and talented people.
- We are a dynamic, R&D-driven organization with a constant focus on innovation and ground-breaking technologies. At Nanomi, initiative is valued, daring is rewarded, and we encourage you to explore and 'push the boundaries!'
- Our team currently consist of about **50 employees**.
- Functions varying from technical functions (e.g. Lab Technician, (Senior) Analytical Chemist, (Senior) Engineer, Scientist, Tech Transfer Specialist etc.) to the general supporting functions e.g. Supply Chain, QA, Project Managers, etc.



### **Competitive Edge: More effective drugs with less side effects**

#### Immediate release

- Toxic drug levels
- Ineffective drug levels
- Multiple injections
- Poor patient compliance



### Long-acting release particles



- More effective
- Less injections (up to 1x/yr)
- High patient compliance



### Traditional long-acting release products

- Pain and swelling
- Poor injectability
- Large needles
- Burst





Phagocytosis by macrophages (red): Swelling and pain

#### Nanomi long-acting release products

#### 30 µm particles

Time -----

Maximum desired level

Minimum effective level

Dose



No phagocytosis of particles

- No immune response
- Excellent injectability
- Small needles
- No Burst



### Developing enhanced applications with the benefits from Nanomi's platforms



**A LUPIN GROUP COMPANY** 

CONFIDENTIAL

#### Two approaches, microspheres and nanoparticles:

- 1. Miscible solvents nanoparticles
  - 'Jetting' of API in a miscible organic solvent into aqueous phase: nanoprecipitation (eg., small molecules)

#### Commercial scale

API in miscible organic solvent



9 CONFIDENTIAL



### Two approaches, microspheres and nanoparticles:

- 1. Miscible solvents nanoparticles
  - 'Jetting' of API in a miscible organic solvent into aqueous phase: nanoprecipitation (eg., small molecules)



Aqueous phase with emulsifier containing **nanoparticles** 

10 CONFIDENTIAL

- 2. Immiscible solvents microspheres
  - Single emulsion droplet generation: o/w (e.g., small molecules)

#### GMP Commercial scale

API and biodegradable polymer in immiscible organic solvent





Aqueous phase with emulsifier containing microdroplets, hardening to **microspheres**, through solvent evaporation.

A LUPIN GROUP COMPANY

### Two approaches, microspheres and nanoparticles:

- 1. Miscible solvents nanoparticles
  - 'Jetting' of API in a miscible organic solvent into aqueous phase: nanoprecipitation (eg., small molecules)

2. Immiscible solvents - microspheres

- Single emulsion droplet generation: o/w (e.g., small molecules)
- Double emulsion droplet generation: w/o/w (e.g., peptides)

#### GMP Commercial scale

API and biodegradable polymer in immiscible organic solvent



Microsieve

nano

A LUPIN GROUP COMPANY

Aqueous phase with emulsifier containing microdroplets, hardening to **microspheres**, through solvent evaporation.



API in

miscible organic solvent

Add-on API in aqueous droplets

in biodegradable polymer in immiscible organic solvent



#### Two approaches, microspheres and nanoparticles:

- 1. Miscible solvents nanoparticles
  - 'Jetting' of API in a miscible organic solvent into aqueous phase: nanoprecipitation (eg., small molecules)



### Two approaches, microspheres and nanoparticles:

- 1. Miscible solvents nanoparticles
  - 'Jetting' of API in a miscible organic solvent into aqueous phase: nanoprecipitation (eg., small molecules)



- 2. Immiscible solvents microspheres
  - Single emulsion droplet generation: o/w (e.g., small molecules)
  - Double emulsion droplet generation: w/o/w (e.g., peptides)





# **Analytical chemistry**

1. Microspheres

2. Nanosuspensions

3. Project phases







# Microspheres

- API loaded polymer -> Drug loading (%) -> HPLC-UV
- Glass transition temperature -> DSC
- Particle size -> Coulter counter
- In vitro release -> Sample & Separate



• Morphology -> SEM



HPLC-UV



# In vitro release microspheres



IVR curve



Accelerated vs normal

Discriminate between polymers

Animal or clinical trial for in vivo data -> IVIVC



### Nanosuspensions

- No polymer -> concentration -> HPLC-UV
- Polymorphic forms -> XRD
- Particle size -> SALD and DCS
- In vitro release -> USP2 dissolution

Nanosuspension



• Morphology -> SEM



**RP-HPLC** 



# Particle size & dissolution



### **Project phases**



**Formulation Lab** Early-phase development



**Cleanroom** Proof-of-concept ATM



**Process Lab** Scale-up to commercial



**GMP factory** Clinical & commercial production

#### 'Scientific sound' + Validated

- High throughput of API's
- Fit for purpose method development
- Limited stability studies

- Validated methods
- GMP
- Large stability studies





# **Questions?**

### or visit our booth for more info

**Chiel Welink** Analytical Chemist





Nanomi BV Zutphenstraat 51 7575 EJ Oldenzaal The Netherlands

Thijs Duursma

Process Development Engineer

+31 880 040 837 www.nanomi.com

